Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus Beck, I. A. Payant, R. /Ngo-Giang-Huong, Nicole Khamduang, W. Laomanit, L. /Jourdain, Gonzague Frenkel, L. M. HBV drug resistance Oligonucleotide ligation assay Lamivudine resistance HBV treatment Treatment of chronic hepatitis B virus (HBV) infection with lamivudine-monotherapy rapidly selects mutant variants in a high proportion of individuals. Monitoring lamivudine resistance by consensus sequencing is costly and insensitive for detection of minority variants. An oligonucleotide ligation assay (OLA) for HBV lamivudine-resistance was developed and compared to consensus sequencing. Both assays detected drug resistance mutations in 35/64 (54.7%) specimens evaluated, and OLA detected minority mutants in an additional six (9.4%). OLA may offer a sensitive and inexpensive alternative to consensus sequencing for detection of HBV drug resistance in resource-limited settings. 2016 text https://www.documentation.ird.fr/hor/fdi:010066848 fdi:010066848 Beck I. A., Payant R., Ngo-Giang-Huong Nicole, Khamduang W., Laomanit L., Jourdain Gonzague, Frenkel L. M.. Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus. 2016, 233, 51-55 EN THAILANDE